Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 781

Sort by

Sort Order Select

Journal Articles

Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

Blood (2020) 136 (10): 1161–1168.

https://doi.org/10.1182/blood.2020005064

Published: 2020

Includes: Supplemental data

Journal Articles

The gut microbial metabolite trimethylamine N -oxide aggravates GVHD by inducing M1 macrophage polarization in mice

Kunpeng Wu, Yan Yuan, Huihui Yu, Xin Dai, Shu Wang, Zhengxu Sun, Fen Wang, He Fei, Qiwang Lin, Hua Jiang, Tong Chen

Blood (2020) 136 (4): 501–515.

https://doi.org/10.1182/blood.2019003990

Published: 2020

Includes: Supplemental data

Journal Articles

Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor–tissue factor axis

Mostafa Belghasem, Daniel Roth, Sean Richards, Marc Arthur Napolene, Joshua Walker, Wenqing Yin, Nkiruka Arinze, Chimera Lyle, Cheryl Spencer, Jean M. Francis, Cristal Thompson, Christopher Andry, Stephen A. Whelan, Norman Lee, Katya Ravid, Vipul C. Chitalia

Blood (2019) 134 (26): 2399–2413.

https://doi.org/10.1182/blood.2019001675

Published: 2019

Includes: Supplemental data

Journal Articles

Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death

Matthew Tcheng, BSc, Alessia Roma, BSc, Nawaz Ahmed, MSc, Richard Smith, PhD, Preethi Jayanth, PhD, Mark D. Minden, MD PhD, Rose Hurren, BSc, Aaron D Schimmer, MD PhD, Gale Bozzo, PhD, David Hess, PhD, Kristin Hope, PhD, Kevin Rea, MSc, Tariq A. Akhtar, PhD, Al-Walid Mohsen, PhD, Jerry Vockley, MD PhD, Paul A. Spagnuolo, PhD

Blood (2019) 134 (Supplement_1): 3922.

https://doi.org/10.1182/blood-2019-122262

Published: 2019

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

https://doi.org/10.1182/blood-2019-131930

Published: 2019

Journal Articles

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 5534.

https://doi.org/10.1182/blood-2019-132001

Published: 2019

Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Blood (2019) 134 (Supplement_1): 4235.

https://doi.org/10.1182/blood-2019-129614

Published: 2019

Journal Articles

Fanconi Anemia: A Paradigm for Understanding DNA Repair During Replication.

Agata Smogorzewska, MD PhD

Blood (2019) 134 (Supplement_1): SCI-32.

https://doi.org/10.1182/blood-2019-121229

Published: 2019

Journal Articles

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Matheus Vescovi, MD PhD, Iara Baldim Rabelo Gomes, MD PhD, Ismael Dale Cotrim Guerreiro da Silva, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2229.

https://doi.org/10.1182/blood-2019-126241

Published: 2019

Journal Articles

Exploitation of a Newly Characterized Metabolic-Cytoskeletal Axis for Effective Combination Therapy of Iron Restricted Anemia

Adam N Goldfarb, MD, Katie Freeman, BA, Alejandro Ariel Gru, MD, Zollie White, III, MS, Lorrie L Delehanty, BS

Blood (2019) 134 (Supplement_1): 2233.

https://doi.org/10.1182/blood-2019-129172

Published: 2019

Journal Articles

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Jing Deng, PhD, Tingting Mao, MS, Xiaojing Huang, PhD, Li Rui, Guangfeng Wang, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2019) 134 (Supplement_1): 2573.

https://doi.org/10.1182/blood-2019-128708

Published: 2019

Journal Articles

Human Acute Leukemia Is Addicted to Branched-Chain Amino Acid Metabolism to Maintain Leukemia Stemness

Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 2516.

https://doi.org/10.1182/blood-2019-129372

Published: 2019

Journal Articles

Separate Roles of Asparagine and Glutamine in Cytostatic Effect of L-Asparaginase - Stable Isotope Tracing Approach

Katerina Hlozkova, PhD, Alpesh Thakker, PhD, Natividad Alquézar-Artieda, Marketa Zaliova, MD PhD, Jan Trka, Prof., MD PhD, Daniel A Tennant, PhD, Julia Starkova, PhD

Blood (2019) 134 (Supplement_1): 2575.

https://doi.org/10.1182/blood-2019-127911

Published: 2019

Journal Articles

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

Metis Hasipek, PhD, Yihong Guan, PhD, Dale Grabowski, BS, Jaroslaw P. Maciejewski, MD PhD, Hetty E. Carraway, MD MBA, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 2553.

https://doi.org/10.1182/blood-2019-130475

Published: 2019

Journal Articles

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Geethu Emily Thomas, PhDMSc,BSc, Grace Egan, MD, Laura Garcia Prat, Boaz Nachmias, MD PhD, Jordan M Chin, Fieke W Hoff, BSc, Kerstin Kaufmann, PhD, Rose Hurren, BSc, Marcela Gronda, MSc, Neil MacLean, Xiaoming Wang, Veronique Voisin, PhD, Aaron Botham, Andrea Arruda, Mark D. Minden, MD PhD, Gary D Bader, Steven M. Kornblau, MD, John E. Dick, PhD, Aaron D Schimmer, MD PhD

Blood (2019) 134 (Supplement_1): 2532.

https://doi.org/10.1182/blood-2019-123121

Published: 2019

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Blood (2019) 134 (Supplement_1): 2591.

https://doi.org/10.1182/blood-2019-127253

Published: 2019

Journal Articles

Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition

Amy N Sexauer, MD PhD, Brian Do, David B Sykes, MD PhD

Blood (2019) 134 (Supplement_1): 2712.

https://doi.org/10.1182/blood-2019-128910

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Michael R. Savona, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Katherine J. Walsh, MD, Raoul Tibes, MD PhD, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Nikolai A. Podoltsev, MD PhD, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 2957.

https://doi.org/10.1182/blood-2019-129962

Published: 2019

Journal Articles

IFNy Stimulation Induces Hematopoietic Stem Cell Homing and Niche Relocalization

Marcus A Florez, BS, Katie A Matatall, PhD, Laura Ortinau, PhD, Roman Jaksik, PhD, Marek Kimmel, PhD DSc, Dongsu Park, PhD, Katherine Y. King, MD PhD

Blood (2019) 134 (Supplement_1): 3726.

https://doi.org/10.1182/blood-2019-130555

Published: 2019

Journal Articles

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

Nick van Gastel, PhD, Jessica B. Spinelli, PhD, Azeem Sharda, MS, Amir Schajnovitz, PhD, Ninib Baryawno, PhD, Catherine S Rhee, PhD, Toshihiko Oki, MD PhD, Eliane Grace, Heather J. Soled, Charles Vidoudez, PhD, Sunia A. Trauger, PhD, Marcia C. Haigis, PhD, David T. Scadden, MD

Blood (2019) 134 (Supplement_1): 3725.

https://doi.org/10.1182/blood-2019-124789

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

The gut microbial metabolite trimethylamine N -oxide aggravates GVHD by inducing M1 macrophage polarization in mice

Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor–tissue factor axis

Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Fanconi Anemia: A Paradigm for Understanding DNA Repair During Replication.

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

Exploitation of a Newly Characterized Metabolic-Cytoskeletal Axis for Effective Combination Therapy of Iron Restricted Anemia

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Human Acute Leukemia Is Addicted to Branched-Chain Amino Acid Metabolism to Maintain Leukemia Stemness

Separate Roles of Asparagine and Glutamine in Cytostatic Effect of L-Asparaginase - Stable Isotope Tracing Approach

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

IFNy Stimulation Induces Hematopoietic Stem Cell Homing and Niche Relocalization

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only